Currently, the analyst consensus on Annexon Biosciences is a Strong Buy with an average price target of $11.00, a 362.18% upside from current levels. In a report released today, Needham also ...

In a report released today, Andrew Tsai from Jefferies maintained a Buy rating on Annexon Biosciences, with a price target of $10.00. The company’s shares closed yesterday at $2.38. Take advantage of ...

XCF Global and OpenSponsorship partner to provide sports, entertainment, and music industries with carbon-neutral air travel ...